There is difference between cell therapy and gene therapy. Some companies do both (BLUE). Modification of CAR T cells is cell therapy. Gene therapy companies, whereby a functioning gene segment is inserted into cells through a viral vector, usually an adeno-associated virus (AAV!, AAV2) are CLDN, ONCE, BLUE, AAVL, AGTC, CURE for starters. CAR T technology is being worked on by BLCM, JUNO, KITE, BLUE, ADAP, CLLS, NVS, XON, ZIOP, and others. I hope that helps.
I'm probably going to hold. I think there's enough institutional interest to absorb the freed up shares, if the insiders sell.
you're a few days behind the curve. It just retraced back to the 55's fropm the 70's and now it's back on it's way up to all time highs.
Ok thx igonber. Congrats btw on staying away from LPTH! Fortunately I turned by shares in for call options so I only lost 25% of the original amount. I'm still in AAVL
Only fools play for pennies sidelurker. And I don't believe you in any case. No one worthy of trading would make that trade. 10,000 shares or 100 calls, maybe, for 12 cents. Otherwise, I have no idea what you're thinking. This could gap up 50 cents or a dollar and ruin your sandcastle!
UBS analyst Andrew Peters weighed in on Achillion Pharmaceuticals on May 20, downgrading his rating from Buy to Neutral and cutting his price target from $19 to $11.50. The analyst attributed his downgrade to the limited potential upside the Achillion and Johnson & Johnson collaboration has for the stock.
Overall, Andrew Peters has a 58% success rate recommending stocks and a +20.7% average return per recommendation.
Similarly on May 20, JMP Securities analyst Liisa Baykodowngraded her rating on Achillion Pharmaceuticals from Outperform to Market Perform with a price target of $24. The analyst believes the deal’s platform “appears to have blockbuster potential” but prefers to hold out until the company starts to benefit from outsourcing its hepatitis C virus pipeline.
Liisa Bayko has an overall success rate of 73% recommending stocks and a +55.2% average return per recommendation.
I'll take Liisa's 73% over Andrew's 58%, and her 55% return per rec over his 20% per rec, however those are calculated.
I couldn't believe that isonep blew up. That was a surprise to say the least. I'm now making a big bet on Avalanche. (AAVL) And Spark (ONCE). If those fail, I'll take a break. I've been up and down )250,000 this year so far, and as of June 1 it looks like I'll break even for the year. I still have 7 months to go!
aside from making money, and purely for entertainment value if nothing else, I sure hope GILD or ABBV or BMY or ALXN, or whomever throws a curve ball into this with a bid. Wouldn't that be fun?
3102 and Olysio are both proven drugs. The only big outstanding question is which nuc will work with the two of them without tox, and will the three play well in the sandbox together. I think we'll find out a lot sooner than people think.
well, I can say this - after looking at ACHN for the remainder of this year, if I get the impression that the stock is in a rut for a long time, I'll sell and move on. Right now I'm sticking around to watch any firework shows.